Gut microbiome alterations precede graft rejection in kidney transplantation patients 1

2	Johannes Holle ^{1,2,3,4} *, Rosa Reitmeir ^{2,3,4} *, Felix Behrens ^{1,2,3,4} , Dharmesh Singh ^{5,6} , Daniela Schindler ⁷ ,
3	Olena Potapenko ^{2,4} , Victoria McParland ^{2,4} , Harithaa Anandakumar ^{2,3,4} , Nele Kanzelmeyer ^{8,9} , Claudia
4	Sommerer ^{10,11} , Steffen Hartleif ^{12,13} , Joachim Andassy ^{6,14} , Uwe Heemann ^{6,15} , Michael Neuenhahn ^{5,6} ,
5	Sofia K. Forslund-Startceva ^{2,3,4} , Markus Gerhard ^{5,6} , Jun Oh ¹⁶ , Nicola Wilck ^{2,3,4,17,#} , Ulrike Löber ^{2,3,4,#} ,
6	Hendrik Bartolomaeus ^{2,3,4,6#} , and members of the German Center of Infection Research Transplant
7	Cohort
8	¹ Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité –
9	Universitätsmedizin Berlin, Berlin, Germany.
10	² Experimental and Clinical Research Center, a cooperation of Charité – Universitätsmedizin Berlin
11	and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
12	³ German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
13	⁴ Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
14	⁵ Department of Preclinical Medicine, Institute for Medical Microbiology, Immunology and Hygiene,
15	Technical University of Munich (TUM), TUM School of Medicine and Health, Munich, Germany
16	⁶ German Center for Infection Research (DZIF), Partner Site München, Germany
17	⁷ German Center for Infection Research (DZIF), Partner Site Braunschweig, Germany
18	⁸ Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Children's
19	Hospital, Hannover, Germany
20	⁹ German Center for Infection Research (DZIF), Partner Site Hannover, Germany
21	¹⁰ Department of Nephrology, University of Heidelberg, Heidelberg, Germany
22	¹¹ German Center for Infection Research (DZIF), Partner Site Heidelberg, Germany

- 23 ¹²Paediatric Gastroenterology and Hepatology, University Children's Hospital Tübingen, Tübingen,
- 24 Germany
- 25 ¹³German Center for Infection Research (DZIF), Partner Site Tübingen, Germany
- 26 ¹⁴Klinik für Allgemeine-, Viszeral-, und Transplantationschirurgie, Klinikum der Universität München,
- 27 Munich, Germany
- 28 ¹⁵Department of Nephrology, Technical University of Munich, Munich, Germany
- 29 ¹⁶Department of Pediatric Nephrology, University Children's Hospital, University Medical Center
- 30 Hamburg-Eppendorf, Hamburg, Germany
- ¹⁷Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin,
- 32 Germany
- 33 *shared contribution
- 34 [#]shared last authorship
- 35
- 36 Correspondence to:
- 37 Johannes Holle, MD
- 38 Experimental and Clinical Research Center (ECRC)
- 39 Charité Universitätsmedizin Berlin
- 40 Lindenberger Weg 80
- 41 13125 Berlin
- 42 Germany
- 43 Mail: johannes-benjamin.holle@charite.de

44 Abstract

45 <u>Background:</u> Kidney transplantation (KT) is the optimal treatment for end-stage kidney disease, with 46 graft survival critically affected by the recipient's immune response. The role of the gut microbiome 47 in modulating this immune response remains underexplored. Our study investigates how 48 microbiome alterations might associate with allograft rejection.

<u>Methods:</u> We analyzed existing biomaterials of a multicenter prospective study involving 217 KT recipients and 28 kidney donors from the German Center for Infection Research. Changes in the gut microbiome were analyzed using 16S rRNA gene amplicon sequencing and functional predictions (PICRUSt2) and quantitative PCRs for the production potential of propionate and butyrate. Propensity score matching was utilized to compare patients who experienced graft rejection with those who did not.

55 Results: The gut microbiome showed gradual recovery post-KT, marked by an increase of Shannon 56 diversity and SCFA-producing bacterial taxa. However, prior to graft rejection, significant alterations 57 were noted in microbiome composition, characterized by a decrease in microbial diversity and SCFA-58 producing taxa. Post-rejection analysis revealed normalization of these microbiome features. 59 Functional analysis highlighted a decreased potential for SCFA production in patients prior to 60 rejection. Comparison to published microbiome signatures from chronic kidney disease (CKD) 61 patients demonstrated a partial overlap of the microbiome alterations preceding graft rejection with 62 the alterations typically found in CKD.

63 <u>Conclusions:</u> Our findings suggest that alterations in the gut microbiome composition and function 64 may precede and influence KT rejection, suggesting potential for use as biomarker and early 65 therapeutic microbiome-targeting interventions to improve transplant outcomes.

66

67 Key points

68	-	CKD-related microbiome alterations recover over time after transplantation mirroring CKD-
69		to-health transition
70	-	Microbiome alterations with lowered production potential of short-chain fatty acids precede
71		graft rejection, likely influencing graft immunity
72	-	The persistence of CKD-associated microbiome characteristics in rejection patients opens
73		avenues for innovative treatment strategies.

75 **1.** Introduction

Kidney transplantation (KT) represents the best treatment option for patients with advanced kidney failure (CKD G5)¹. Despite ongoing efforts to prevent the progression of CKD and related comorbidities, successful KT and graft survival, especially prevention of graft rejection, are of outmost importance. Graft rejection is the medium- and long-term complication with highest impact on graft and subsequently recipient survival². Whether a patient experiences acute or chronic graft rejection or not is, according to the current scientific understanding, largely dependent on immune mechanisms, the modifiers of which still remain poorly understood³.

83 Of late, the gut microbiome gained considerable attention as key modulator of the immune system in both healthy and disease conditions⁴. Microbiota, their metabolites and associated molecules 84 85 interact with numerous host organs including mucosa-associated and systemic immune cells and 86 thereby shape host immunity and inflammation⁵. Patients with CKD exhibit marked alterations to their gut microbiome composition and subsequent dysregulation of metabolite abundance⁶. In 87 particular, a switch from saccharolytic to proteolytic fermentation is observed⁷. On one hand this 88 leads to lower intestinal and systemic concentrations of short-chain fatty acids (SCFA)⁸, previously 89 90 identified as inducers of regulatory immunity⁹. On the other hand, increased levels of pro-91 inflammatory metabolites, such as tryptophan-derived indoxyl sulfate, are observed⁸.

92 After KT, CKD-related microbiome alterations can partially persist, presumably by contribution of additional factors such as immunosuppression¹⁰, and are associated with clinical events like post-93 transplant diarrhea^{11,12}. A recent study rigorously demonstrated an association between lower gut 94 95 microbial diversity in patients with solid organ transplantation and increased overall mortality¹³. A 96 growing body of evidence implicates the gut microbiota in alloimmunity and graft rejection. Germ-97 free mice and mice treated with antibiotics show prolonged skin graft survival compared to conventional mice, suggesting that alloimmunity is modulated by microbiota¹⁴. Furthermore, recent 98 99 studies indicate that gut microbes directly affect immune-regulatory cells (regulatory T cells, Th17

100 cells)^{15,16}, with SCFA playing a central role in this relationship¹⁷. Studies in mice showed that SCFA 101 supplementation mediates donor-specific tolerance to kidney allograft through induction of Foxp3⁺ 102 regulatory T-cells¹⁸. Finally, human interventional studies are underway, aiming to improve CKD-103 associated microbiome alterations by prebiotic inulin supplementation¹⁹ or at improving immune 104 regulation by supplementation of regulatory T cells²⁰.

105 In this study, we analyzed longitudinal changes in the composition and function of the gut 106 microbiome of KT recipients enrolled in the transplant cohort (Tx cohort) of the German Center of 107 Infectious Diseases (DZIF)²¹ and connect them with the clinical outcomes, specifically graft survival 108 and rejection. In a propensity score-matched subcohort we identify microbial alterations preceding 109 graft rejections and transplant dysfunction.

111 **2.** Materials and methods

112 Study Population and Design

All patients analyzed in this study were part of the Tx cohort of the DZIF, which is a multicenter prospective cohort study conducted at four German transplant centers (University Hospitals in Heidelberg, Munich (Technical University and Ludwig Maximilian University) and Tübingen)²¹. Together, these centers cover over 20% of solid organ transplants in Germany²² providing a representative picture of post-transplant course in Germany.

118 For the present study, we analyzed data from all kidney allograft recipients who consented to 119 participate and received a kidney transplant between July 2014 and July 2021. Samples were 120 collected between March 2017 and September 2021. Patients receiving multi-organ transplantation 121 or patients who underwent previous solid organ transplantation were excluded (Supplemental 122 Figure 1). Moreover, participants without fecal samples were excluded from our analysis. Ethics 123 approval was obtained from all participating centers (Heidelberg #S-585/2013, TU Munich #5926/13, 124 LMU Munich #380-15, Tübingen #327/2014BO1), and all participants provided written informed 125 consent. The experimental analysis of fecal samples, including metadata analysis, was approved by 126 the ethics board of Charité – Universitätsmedizin Berlin (EA2/208/21).

127 The study design, including biomaterial collection, was described previously²¹. Fecal samples were 128 collected using DNA stabilizing buffer (STRATEC). Study visits were performed immediately before 129 KT, at months 3, 6, 9, and 12 after KT and when infections or rejection events were detected. Clinical 130 and laboratory data were collected at each study visit.

131 Standard of care treatment

The patients received a standard triple-drug combination of immunosuppressants (comprising acalcineurin inhibitor, mycophenolate (MPA), and corticosteroids), initially frequently together with

an interleukin 2 receptor antagonist (basiliximab). The prophylaxis and surveillance strategy for
 infectious complications was suggested to be performed according to KDIGO 2009 guidelines²³,
 including antiviral prophylaxis with valganciclovir for patients at high risk for cytomegalovirus (CMV)
 infections, trimethoprim-sulfamethoxazole prophylaxis against *Pneumocystis jirovecii* and urinary
 tract infections, *Candida* prophylaxis with oral nystatin or amphotericin B.

139 Matching of rejection/non-rejection patients

We conducted our analysis using R (4.3.2), employing MatchIt (4.5.5)²⁴ package for sample matching. 140 141 Patients with histologically proven rejection events were assessed (T cell-mediated rejection (TCMR, Banff category 4) and Borderline (Suspicious) for acute TCMR (Banff category 3))²⁵, if the rejection 142 143 occurred within five years after KT and fecal sampling was obtained before the rejection event (time 144 frame 781 days before the rejection till 3 days after rejection). Patients without sample before 145 rejection and those with-mediated rejection (ABMR) were excluded from the analyses, yielding 33 146 patients with rejection events. Stool samples taken closest before the rejection event were selected 147 for analyses. Control samples were matched based on the absence of rejection and similar baseline 148 characteristics, using nearest neighbour matching with a 2:1 ratio, matching two controls for each 149 rejection case based on the factors primary condition, donor type, time since transplantation, age, 150 and gender. Of the selected 99 patients, one rejection patient was excluded because of primary graft 151 dysfunction (patient still required dialysis three months after KT) and six patients without rejection 152 were excluded because of sustained poor kidney function (plasma creatinine > 2.5 mg/dL).

Detailed information on clinical data preparation, sample collection and processing, 16S amplicon sequencing, SCFA production gene targeting assay (qPCR) and re-analysis of the CKD dataset²⁶ can be found in the online only supplemental material.

156 Statistical Analysis

157 Continuous variables were expressed as medians and interquartile ranges (IQRs). Categorical
158 variables were presented as numbers and percentages. All statistical analyses were conducted using
159 R (4.2.3).

Analysis of alpha diversity and multivariate analysis: Alpha diversity and multivariate analysis were performed on OTU level on the non-rarefied data. Different metrics for alpha Diversities were calculated using the R-package microbiome (v.1.12.0)²⁷. Differences in alpha Diversity were tested using Wilcoxon rank sum test on a significance level of 0.05. For multivariate analysis, Bray-Curtis indices were obtained using the R-package phyloseq (v.1.34.0)²⁸ and tested via PERMANOVA using adonis2 of the R-package vegan (v.2.6-4)²⁹.

166 <u>Cross-sectional comparison:</u> For the association analysis, the R-package metadecondfoundR (v.0.2.8) 167 was used³⁰. The testing was performed on the rarefied data (minimum read count 10270 reads) and 168 all taxonomic levels with a minimum prevalence of 0.1. Wilcoxon rank sum test was performed for 169 binary variables, Spearman's correlation for continuous variables, and Kruskal-Wallis test for ordinal 170 variables. The obtained p-values were adjusted using the Benjamini-Hochberg false discovery rate 171 (FDR) correction. In total, 65 clinical variables were considered as confounding factors (Supplemental 172 Table 1). An association was considered statistically significant when FDR < 0.1.</p>

For individual comparisons of clinical and qPCR parameters, Mann-Whitney U test was performed and p < 0.05 was considered statistically significant.

Longitudinal Analysis: For the longitudinal analysis, LongDat (v.1.1.2)³¹ was used, building negative
 binomial generalized linear mixed models over time after KT, controlling for sample origin by a
 random intercept. The models were built on rarefied data with default filtering³¹. FDR was controlled
 by Benjamini-Hochberg procedure. A change in abundance over time as considered statistically
 significant when FDR < 0.1.

Diversity parameters during different periods before and after KT were compared using MannWhitney U test and p < 0.05 was considered statistically significant.

182 <u>Functional capacity prediction using Picrust2</u>: PICRUSt2³² obtained abundances of the KEGG

- 183 orthologs (KOs) were z-score scaled and tested for significance with a linear model correcting for age
- and sex (Benjamini-Hochberg-corrected FDR < 0.05). All significant KOs were mapped to the
- 185 corresponding GOmixer modules³³ and tested for group difference using Wilcoxon rank sum test
- 186 with a significance level of FDR < 0.05 using the online tools of GOmixer.

188 **3. Results**

189 Gut microbiota composition recovers gradually post-kidney transplantation

We used medical data and fecal samples from the DZIF Transplant Cohort. This multi-center cohort consists of nearly 2400 patients undergoing solid organ transplantation. Here, we focused on fecal samples from patients undergoing KT (n=562 samples, from n= 245 individuals), including kidney donors (n=28) and, if available, pre-transplantation samples (n=26). Baseline characteristics of the cohort can be found in Table 1.

195 We analyzed the microbiome composition using 16S rRNA gene amplicon sequencing. For 196 longitudinal analysis post-KT, samples were grouped according to sampling time, namely 0-3 months 197 (n=69), 3-12 months (n=226) 12-24 months (n=94), 24-36 (n=66), and over 36 months (n=53) post-KT 198 (Supplemental Figure 1). Principal Coordinates Analysis (PCoA) of Bray-Curtis dissimilarity revealed 199 an overall stable microbiome composition post-KT, while the healthy donors and pre-KT groups 200 differed (Fig 1A). While the detected number of operational taxonomic units (OTU, a proxy for 201 bacterial taxa) was mostly stable post-transplantation (Fig 1B), we observed significant shifts in the 202 alpha diversity as quantified by Shannon diversity index (Fig 1C). While Shannon diversity decreased 203 before and in the first year after transplantation, it gradually increased again over time post-KT. We 204 observed a similar trend for Simpson evenness, although most comparisons were not significant (Fig 205 1D).

We performed longitudinal analysis using LongDat³¹ to identify bacterial taxa regulated over time post-KT. Post-transplantation, typical SCFA-producing genera like *Coprococcus*³⁴, *Lachnospiraceae*³⁵, *Roseburia*³⁶, *Faecalibacteria*³⁷ and *Ruminocococcus* torques group³⁸ increased significantly over time (Fig 1E), suggesting an improvement of CKD-associated microbiome alterations, specifically the impaired production of SCFA as one of its hallmarks^{6,8}. Furthermore, we observed a decrease in *Streptococcus*, which was recently linked with subclinical atherosclerosis³⁹ (Fig 1E). In summary, our

analysis demonstrates a dynamic regeneration of the microbiome over time after KT towards a more

213 physiological state after three years or more post-KT.

214 Kidney transplant rejection profoundly impacts microbiome composition

215 Since we observed dynamic microbiome changes over time in KT patients, we aimed to understand 216 how transplant rejection events influence this process and, vice versa, how microbiome alterations 217 may impact allograft immunity. Therefore, we identified fecal samples (n = 157) from patients (n = 76)218 with biopsy-proven rejection events at any timepoint after KT (Table 1). PCoA of Bray-Curtis 219 dissimilarity showed a distinct clustering of patients experiencing graft rejection compared to KT 220 patients with no reported rejection (Fig 1F). While the number of detected OTUs was constant over 221 time (Supplemental Figure 2), Shannon diversity and Simpson evenness were reduced during the 222 first year post-transplantation in rejection patients (Fig 1G-H), which was co-incident with the 223 allograft rejection. Lastly, we performed univariate analyses on genus level using metadeconfoundR³⁰. Corresponding to the altered composition in the multivariate analysis, we 224 225 found a large number of differentially abundant genera (Supplemental Figure 3). Interestingly, the 226 majority of observed effects related to rejection showed a contrasting trend in correlation with the 227 duration between sampling and kidney transplant rejection event (Fig S3). This correlation indicates 228 either microbiome alteration preceding the rejection event, changes in the microbiome post-229 rejection, or both. Of note, our analysis indicates that many effects were confounded by patient age 230 and distance to KT.

Taken together, patients who experience KT rejection have an altered gut microbiome composition.
We hypothesize, that these changes might precede transplant rejection, as the alterations associate
with the time between sampling and KT rejection event.

234 Microbiome alterations precede kidney transplant rejection

To overcome the inherent limitations of the cohort that is unequally distributed age and distance to KT of rejection and non-rejection patients and to further understand which alterations to the microbiome precede KT rejection, we performed propensity score matching of patients with available fecal samples before KT rejection to patients without KT rejection. Matched pre-rejection and non-rejection groups were comparable in age, sex, donor type, underlying CKD disease category and time between KT and sample (Supplemental Figure 4). Baseline characteristics of this subgroup of patients are shown in Table 2.

242 Rejection patients exhibited impaired renal function as compared to non-rejection patients as 243 displayed by an increase in plasma creatinine within the first year post-KT, which remained the case 244 during follow-up (Fig 2A). This corresponds to most rejections in our cohort occurring within one 245 year post-KT (Table 1 and 2). However, both rejection and normal progress patients reached a 246 similar minimal creatinine as well as time to minimal creatinine (Fig 2B), indicating that initial graft 247 function was comparable between both groups. After the rejection event, kidney transplants 248 showed sustained graft dysfunction as indicated by higher minimal detected creatinine values after 249 their rejection event as well as higher last recorded creatinine (Fig 2B). Of note, HLA mismatch 250 grade, rate of AB0 incompatibility and delayed graft function were comparable between both groups 251 (Table 2).

252 Microbiome analysis indicated alterations prior to the rejection event. Pre-rejection microbiome 253 composition was characterized by a distinct composition indicated by different clustering in the 254 PCoA of Bray-Curtis dissimilarity (Fig 2C), and lower alpha-diversity, reaching significance for 255 Simpson evenness (Fig 2D). Patients who rejected the transplanted kidney had lower level of known 256 SCFA producers on genus level, like *Blautia*, *Clostridia*, or *Ruminococcus* torques group³⁸. 257 Interestingly, we observed an increase in bacteria typically found in CKD patients, like Fusobacterium⁸, and disease-associated genera⁴⁰, such as Strepcoccus³⁹ and Porphyromonas⁴¹ (Fig 258 259 2E).

260 Despite our efforts to closely match the rejection and non-rejection groups, a higher rate of viral 261 infections was observed in the rejection group. We therefore carefully assessed the use of 262 immunosuppressants and anti-infective medication (Supplemental Figures 5-7), pointing out two 263 main differences, namely a lower number of patients on MPA at sampling date – likely due to the 264 viral complications – and a lower number of patients with basiliximab for induction in the rejection group. Multivariate analysis revealed no difference in microbiome composition in rejection patients 265 266 with or without basiliximab induction (Supplemental Figure 8), but MPA withdrawal showed a non-267 significant shift in microbiome composition. Therefore, we performed the genus level differential 268 abundance analysis, including and excluding patients with MPA discontinuation, which closely 269 correlated (R= 0.98, p< 0.001) (Supplemental Figure 9). This indicates that the observed differences 270 were independent of basiliximab induction or MPA discontinuation, respectively.

271 Lower SCFA production potential characterizes the pre-rejection microbiome

272 Metabolites produced by microbiota are known to influence and modulate host immune responses. 273 To identify potential candidates, we analyzed functional capacities, predicted from our taxonomic data using PICRUSt2³², identifying functional pathways in the significantly altered KOs using 274 GOmixer^{33,42}. We observed an overall clustering of rejection and non-rejection patients in the PCA 275 276 (Fig 3A). We found an enrichment in proteolytic fermentation, reactive nitrogen and oxygen species, 277 and ammonia pathways in the rejection group (Fig 3B, C). Conversely, overall sugar and 278 polysaccharide utilization and mucus degradation were enriched in microbiomes from non-rejection 279 controls (Fig 3B, C). Matching to the reduced number of SCFA-producing genera we found a 280 reduction in butyrate and acetate fermentation pathways (Fig 3B, C), again highlighting the 281 reduction of SCFA production in stool samples preceding KT rejection (Fig 3B, C). Since SCFA and 282 regulatory immune functions are closely linked, we aimed to confirm the reduction of SCFA 283 production using qPCR measuring key enzymes for butyrate and propionate production. Overall, we 284 found a significant reduction of butyryl-CoA:acetate CoA-transferase (but), a key enzyme for

butyrate production, and methylmalonyl-CoA decarboxylase (*mmdA*), a key enzyme for propionate production (Fig 4A, B). Another central enzyme for butyrate synthesis, butyryl-CoA dehydrogenasee (*bcd*), was reduced without reaching significance (Fig 4A, B). Taken together, a key feature of the gut microbiome in samples from patients preceding KT rejection is a marked reduction of the potential to produce SCFA.

290 Microbiome alterations normalize post-rejection

291 As our initial analysis indicated a potential shift post-rejection, we analyzed longitudinal samples 292 from our matched cohort within a timeframe of 90 to 1000 days after the first sample (n=21 293 rejection and n=54 non-rejection patients). PCoA using Bray-Curtis dissimilarity shows that the 294 microbiome composition becomes more similar to the non-rejection control group in post-rejection 295 samples (Fig 5A). Over a similar time frame the microbiome composition of non-rejection controls 296 was stable. The same trend could be observed for the number of detected OTUs, Shannon diversity 297 and Simpson evenness (Fig 5B). Next, we analyzed microbiome alterations post-rejection on genus 298 level (Fig 5C). While the non-rejection control showed no significant alterations, most genera 299 dysregulated preceding rejection were significantly changed in the opposite direction after the KT 300 rejection event (Fig 5C). Especially known genera of SCFA production like Blautia and 301 Faecalibacterium increased, while disease-associated genera like Fusobacterium and Streptococcus 302 decreased (Fig 5D).

Taken together, we observe a normalization of the pre-rejection microbiome towards the normal KT signature in a longitudinal follow-up analysis. One could speculate that a lack of normalization of the microbiome favors chronic rejections. Due to insufficient sample size, we could not further test this hypothesis in this study.

307 The microbiome signature in kidney transplant rejection is a prolonged CKD signature

308 Lastly, we aimed to contextualize the microbiome alteration preceding KT rejection. We observed a 309 partial overlap with a microbiome features of pediatric CKD patients recently published by us⁸. 310 Therefore, we hypothesized that the microbiome alterations preceding KT rejection in parts reflects 311 a prolonged CKD signature after KT. Therefore, we re-analyzed a recently published 16S rRNA gene 312 sequencing dataset from CKD patients (n=217) and healthy controls (n=479)²⁶. In line with our 313 hypothesis, the KT rejection signature correlated with the CKD signature in the dataset from Ren et 314 al. (for the 120 common genera, R= 0.19, p= 0.033) (Fig 6A). In particular, the overlap of both 315 datasets also held true for the reduction of important SCFA producers like Blautia and 316 *Faecalibacterium*, as well as for the increase in *Streptococcus* and *Fusobacterium*, with the latter not 317 reaching significance in the CKD-HC comparison (Fig 6A, B). Lastly, we performed a targeted analysis 318 of bacterial taxa captured by our but, bcd and mmdA assays. Overall, the abundance of butyrate and 319 propionate producing taxa was lower in CKD patients mirroring the effect we observed in 320 microbiome samples preceding KT rejection (Fig 6C).

In aggregate, our data indicate that the pre-rejection signature we observed in our cohort might in
part be a sustained CKD signature. Especially the lack of fiber fermenting, SCFA-producing bacteria is
a key feature found in both disease states.

324 **4. Discussion**

In the present study, we investigate the gut microbiome in KT recipients and its relationship with allograft rejection. KT remains the best treatment option for patients with advanced and dialysisdependent CKD, but graft availability is limited. Therefore, the improvement of graft survival and prevention of allograft rejection are paramount. For the first time, we describe compositional and functional differences in the microbiome in a representative cohort of 217 transplant patients with and without rejection, which are of potential prognostic and therapeutic value.

331 Our analysis of longitudinally collected fecal samples unveils a dynamic trajectory of microbiome 332 recovery post KT, which undertakes a gradual shift towards a more stable and healthier microbiota 333 composition⁴⁰ over time. This gradual process is marked by the enrichment of bacterial taxa 334 associated with short-chain fatty acid (SCFA) production (such as Roseburia, Faecalibacterium), and a 335 loss of disease-associated taxa (such as Streptococcus). These regenerative microbiome shifts post 336 KT are significantly perturbed in the case of graft rejection. Preceding the rejection event, we 337 observed profound alterations in microbiome composition, characterized by a diminished diversity 338 and underrepresentation of SCFA-producing bacterial populations. Notably, these alterations tend to 339 normalize post KT rejection events. We consider these observations to be of potential functional 340 relevance for allograft immunity due to the known immunomodulatory properties of SCFA 341 reference^{9,17}. Although our study was not designed to show causality, our results suggest that the 342 microbiome is an important modulator of immunologic events after KT - an observation that may 343 also have prognostic significance for the prevention of KT rejection and graft survival.

The observed gradual normalization of the microbiome composition after KT aligns for several bacterial taxa the normalization of known alterations in the gut microbiome of CKD patients. The gut microbiome of CKD patients is relatively well investigated. It is characterized by a lower diversity and a shift in metabolic output^{6,8,26,43}. While the production of SCFA metabolites, recognized for their anti-inflammatory effects⁹, is reduced⁸, we and others have observed an increase in the production

of microbiome-derived uremic toxins like TMA⁴⁴, p-cresols⁴⁵ and indoles^{8,46}. Of note, the microbiome 349 350 of CKD patients is characterized by an increase of bacterial taxa frequently linked to health-todisease transition in large representative metagenomic studies^{40,47}. In the present study, we observe 351 352 a decrease of known pathogenic bacteria and increase in beneficial commensals over the course of 353 more than three years post KT. Thus, the observed changes are reminiscent of a CKD-to-health 354 transition in the microbiome. Dysbiotic microbiome states in KT patients have been described by 355 others^{10,13}. Swarte and colleagues demonstrated that lower gut microbial diversity in kidney and liver transplant recipients is associated with an increased overall mortality¹³. As graft survival is the most 356 important predictor of overall medium- and long-term survival after KT², we hypothesize that gut 357 358 bacterial diversity may also be important for graft survival.

359 We demonstrate that alterations of the gut microbiome, including a reduced microbial diversity, and 360 alterations in the abundance of more than 50 bacterial taxa, occur before graft rejection. 361 Microbiome composition preceding graft rejection was characterized by several typical disease-362 associated species. Most prominent and similar to the analyzed CKD signature, we found an increase 363 in Streptococcus. Streptococcus spp. were recently correlated to subclinical atherosclerotic lesions in a cohort of nearly 9000 patients³⁹. Another genus found to be upregulated in rejection and CKD 364 (although not reaching significance in the cohort we reanalyzed²⁶ as compared to other studies⁸) was 365 366 Fusobacterium. Fusobacterium nucleatum was recently described as a driver of uremic toxins 367 production and CKD progression⁴³, again underscoring the notion of a prolonged CKD signature in 368 the microbiome as a potential risk factor for graft rejection. We and others have shown that SCFA 369 are relevant bacterial metabolites for immune homeostasis in CKD as well as for other chronic diseases^{8,17,48-50}. Using computational prediction of functional microbiome properties (PICRUSt2³²). 370 371 we show a significantly reduced potential of the gut microbiome to produce SCFA. PICRUSt2 predicts 372 microbiome functions such as SCFA production based on the available genomic data and the inferred presence of genes from closely related taxa³². PICRUSt accuracy significantly decreases for microbes 373 with fewer close relatives in reference databases⁵¹. Acknowledging this limitation, we validated the 374

375 regulation of several key enzymes for SCFA synthesis using gene targeting qPCR assays. Therefore,

the microbiome may be functionally implied in the development of graft rejection.

377 A recent meta-analysis concluded that immune cell therapies, including transfer of regulatory T cells (Treg), are a useful approach to reduce immunosuppression during KT²⁰. The findings of our study 378 379 and others suggest that SCFA warrant scientific attention as Treg-modulating bacterial metabolites. 380 SCFA have been shown to influence the function and differentiation of Treg both through GPR signaling and HDAC inhibition^{9,52}. Experimental transplantation models demonstrate the efficacy of 381 382 SCFA treatments through induction of Treg. Kidney transplants showed a prolonged survival in animals fed a high fiber diet or directly the SCFA acetate⁵³. Thus, the rapid attainment of a healthy 383 384 SCFA production potential could be relevant for Treg function and the prevention of rejection events 385 as well as other comorbidities found after KT⁵⁴.

386 Two recent smaller studies similarly suggest alterations of the microbiome in patients with acute rejection (n=3 patients, including both TCMR and antibody-mediated rejection)⁵⁵ or patients with 387 antibody-mediated rejection (n=24)⁵⁶. While the first study is severely limited by its low sample size, 388 389 the second study – albeit focusing on ABMR compared to our focus on TCMR – described on a broad 390 scale similar features like a reduced alpha diversity. Of note, the observed microbiome alterations in 391 our study preceding rejection events normalized during longitudinal follow-up. Future studies are 392 needed to investigate whether persistent microbiome alterations influence the risk for chronic 393 rejection.

The circumstance that fecal samples were not consistently available from all patients at all timepoints in our multi-center cohort limits the validity of our study. However, in non-rejection patients a minimum sample number of two stool samples per patient was not undercut, which enabled the longitudinal character of our study. Despite this, our findings clearly indicate a gradual shift towards a more stable microbiome state post-transplantation. A further limitation is the lack of metabolomic measurements in our study, which we replaced with specific quantifications of the

400	microbial enzyme composition. Finally, the study design does not allow causal statements on the
401	mechanistic significance of microbiome changes for rejection. However, our conclusions regarding
402	the role of SCFA for Treg function are broadly based and supported by published experimental data.
403	Future studies should consider functional data on immune cells and their relationship to microbiome
404	and rejection to validate our conclusions.
405	Taken together, we demonstrate a disrupted microbiome recovery post KT as a novel modifying
406	factor in graft survival. This is to our knowledge the first study indicating that microbiome alterations

407 and perturbation of microbial metabolism precede graft rejection. More studies are needed to

- 408 decipher the interaction of SCFA and Treg in KT patients and to test the potential of microbiome-
- 409 targeting interventions before and after KT to improve long term graft survival.

411 Funding

412 This study was conducted with resources provided by the DZIF transplant cohort e.V. 413 (https://www.dzif.de/en/working-group/transplant-cohort), support code TTU 07.701, and 414 additional DZIF funding under TTU 07.916 to M. Gerhard, D. Schinderl and J. Holle. J Holle was 415 supported by the Else Kröner-Fresenius Stiftung (2023_EKEA.127). N. Wilck was supported by the 416 European Research Council under the European Union's Horizon 2020 research and innovation 417 program grant 852796 and by the Corona Foundation in the German Stifterverband. H. 418 Bartolomaeus and N. Wilck were supported by the BMBF, Foerderkennzeichen 01EJ2202A (TAhRget 419 consortium).

420 Acknowledgement

We thank the members of the German Center of Infection Research Transplant Cohort, in particular
the members of the executive board and the scientific steering committee: Dr. Susanne Delecluse,
Dr. Tina Ganzenmüller, Dr. Bärbel Fösel, Dr, Caroline Klett-Tammen, Dr. Thomas F. Schulz, Dr. Uwe
Heemann, Dr. Thomas Giese, Dr. Philip Ehlermann, Dr. Rasmus Rivinius, Dr. Uta Merle, Dr. Peter
Lang, Dr. Martin Hildebrandt, Dr. Christine S. Falk, Dr. Burkhard Tönshoff, Dr. Anette Melk, Dr.
Thomas Illig, Dr. Berit Lange, and Dr. Thomas Iftner.

427 Data sharing statement

Deidentified metagenomic sequencing data for samples of the Transplant Cohort of the DZIF can be accessed from the European Nucleotide Archive under accession number PRJNA1106540 (https://www.ebi.ac.uk/ena/browser/view/PRJNA1106540). Access to pseudonymized phenotype data requires approval from the scientific steering committee of the DZIF Transplant cohort. The source code and the summary data underlying all figures used to generate the results for the analysis are available at https://github.com/rosareitmeir/DZIF-Tx-Cohort-Data-Cleaning-and-Statistical-Analysis.

436 Supplemental Material

437 Supplemental Figures

438 **Supplemental Figure 1. Study design.** Flow chart of the study design with inclusion and exclusion of

439 patients and final sample number.

Supplemental Figure 2. Observed OTU in rejection (red) and non-rejection (blue) patients.
Horizontal lines indicate the number of detected OTU, shaded area is the 95% confidence interval.
Vertical lines on top of the x-axis indicate rejection events.

Supplemental Figure 3. Impact of rejection state on gut microbiome composition. Analysis of fecal samples from patients experiencing kidney rejection at any time compared to patients never experiencing graft rejection. Heatmap showing associations of bacterial genera with kidney transplant rejection. Meta-variables with significant association are shown. Stars indicate deconfounded significant associations; grey dots indicate confounded associations. °/*FDR< 0.1, °°/**FDR< 0.01, °°°/***FDR< 0.001.

Supplemental Figure 4: Matching of rejection and non-rejection patients. Plots indicate
 metavariables before (left) and after propensity score matching (right). Grey bars/ histogram
 indicate non-rejection before (left) and after (right) propensity score matching. Rejection is shown in
 black.

453 Supplemental Figure 5: Immunosuppressive treatment at the time of transplantation (A) and at 454 the time of fecal sampling (B). Fecal samples were analysed from patients before experiencing graft 455 rejection (Rejection, red) and propensity score matched (1:2) controls (normal progress, blue). Bar 456 plots indicate medication at A) transplantation and B) fecal sampling.

457 Supplemental Figure 6. Tacrolimus plasma levels in matched rejection and non-rejection patients.
458 A) Tacrolimus plasma levels of n=92 patients (matched cohort) for the time between transplantation
459 and sample collection before rejection event (n=121 data points of 51 patients for non-rejection and
460 51 data points of 23 patients for rejection group). B) Difference of target to actual values of
461 Tacrolimus. Target values have been determined by the respective clinical recommendations after
462 kidney transplantation.

Supplemental Figure 7: Anti-infective medications used between kidney transplantation and fecal
 sampling. Anti-infective medication used between kidney transplantation and fecal sampling for the
 matched cohort (normal progress, blue; rejection, red). Medication used both preventive and
 therapeutic is shown.

467 **Supplemental Figure 8: Impact of basiliximab induction therapy on the gut microbiome** 468 **composition.** PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection patients 469 with (brown) and without (orange) basiliximab use during induction. Statistical testing using 470 PERMANOVA shows no difference.

471 Supplemental Figure 9: Impact of mycophenole (MPA) withdrawal on the gut microbiome 472 composition. A) PCoA on Bray-Curtis Dissimilarity of the 16S amplicon sequencing in rejection 473 patients with (light green) and without (dark green) MPA at fecal sampling. Statistical testing using 474 PERMANOVA shows no difference, although some distinct clustering can be seen. B) Correlation of 475 effect sizes in the whole rejection cohort (x-axis) and the cohort excluding patients with MPA 476 withdrawing (y-axis). Axis shows Cliff's deltas for all detected genera in the gut microbiome. 477 Spearman correlations, individual significances for genera using univariate testing in 478 metadeconfoundR.

479

480 Supplemental Tables

- 481 **Supplemental Table 1:** Clinical variables used for deconfounding of microbiome features
- 482 **Supplemental Table 2:** Primers used for 16S sequencing.
- 483 Supplemental Table 3: Bacterial species included to the gene targeting assays for butyrate and
 484 propionate synthesis and corresponding primer sequences.

486 Tables

- 487 Table 1. Clinical baseline characteristics total cohort. Kidney transplant (KT) donors, pre-KT CKD
- 488 patients and post-KT CKD patients from the transplant cohort of the German Center of Infectious
- 489 Diseases (DZIF) were analyzed in this study. Data are presented as median and interquartile range or
- 490 absolute values and percentages as appropriate.

	donors	pre-KT	post-KT	N
individuals (N)	28	26	213	
samples	28	26	508	
samples per participant	1	1	2 (2-3)	
age (years)	53 (46-68)	52 (34-60)	54 (40-63)	28, 26, 213
female	20 (71%)	6 (25%)	70 (33%)	28, 24, 211
BMI (kg/m²)	26.1 (24.0-28.3)	25.1 (21.6-27.3)	24.6 (21.6-28.0) 22, 26, 210
time since KT (days)	NA	NA	294 (148-715)	213
living donor	NA	NA	81 (38%)	212
ABO incompatible KT	NA	NA	18 (9%)	204
rejection	NA	NA	76 (35%)	213
kidney diagnosis				26, 213
cystic	NA	4 (15%)	43 (20%)	
diabetic	NA	2 (8%)	14 (7%)	
glomerular	NA	10 (38%)	71 (33%)	
hereditary/congenital	NA	6 (23%)	25 (12%)	
hypertensive	NA	0	16 (8%)	
other/unknown	NA	4 (15%)	37 (17%)	
tubulointerstitial	NA	0	7 (3%)	
primary graft dysfunction	NA	NA	8 (4%)	209
delayed graft function	NA	NA	38 (18%)	218
in-patient length of stay	NA	NA	19 (14-26)	210

Table 2. Clinical baseline characteristics of the propensity score-matched cohort. Kidney transplant (KT) recipients from the transplant cohort of the German Center of Infectious Diseases (DZIF) were analyzed in this study. Samples were obtained after KT from all patients, but before rejection in the rejection group. Data are presented as median and interquartile range or absolute values and percentages as appropriate. Primary graft dysfunction: patient still required dialysis three months after KT. Delayed graft function: patient required one to three dialysis treatments after KT.

	non-rejection	rejection	all	Ν
individuals (N)	60	32	92	
age (years)	55 (44-63)	58 (47-62)	56 (45-63)	92
female	22 (37%)	11 (34%)	33 (36%)	92
BMI (kg/m²)	23.4 (20.8-27.6)	24.6 (21.5-27.2)	24.1 (21.1-27.5)	92
sample days after KT	111 (85-175)	114 (84-192)	112 (85-181)	92
rejection days after KT	NA	173 (132-282)	NA	92
living donor	20 (33%)	10 (31%)	30 (33%)	92
ABO incompatible KT	5 (8%)	1 (3%)	6 (7%)	92
HLA mismatches (HLA-A, HLA-B, HLA-DR)	2 (2-3)	3 (2-4)	3 (2-4)	79
primary graft dysfunction	0	0	0	88
delayed graft function	9 (15%)	2 (6%)	11 (12%)	92
in-patient length of stay (days)	19 (14-24)	18 (14-26)	19 (14-24)	91
recipient CMV ⁺	26 (46%)	14 (47%)	40 (46%)	87
recipient EBV^{\star}	35 (83%)	18 (90%)	53 (85%)	62
bacterial infections before sample	32	20	52	92
patients with bacterial infection before	17 (700/)	20 (240/)	27 (40%)	02
sample	17 (20%)	20 (34 %)	57 (40%)	92
viral infections before sample	12	23	35	92
patients with viral infection before sample	9 (15%)	14 (44%)	23 (25%)	92

498

500 Figure legends

501 Figure 1. Longitudinal changes to the gut microbiome after kidney transplantation and impact of 502 allograft rejection. 16S rRNA gene amplicon sequencing from fecal material from kidney 503 transplantation (KT)-related samples from the transplant cohort of the German Center of Infectious 504 Diseases (DZIF). Samples were grouped according to healthy kidney donors, pre-KT, 0-3 months post-505 KT, 3-12 months, 12-24 months and over 24 months. A) PCoA based on Bray-Curtis dissimilarity. 506 Quantification of the B) Number of detected OTU, C) Shannon diversity, and D) Simpson evenness. E) 507 Cuneiform plot displaying significantly altered bacteria post-transplantation over time. Microbial 508 diversity in kidney transplant recipients with and without graft rejection at any point is shown in F-H. 509 F) Principal Coordinates Analysis (PCoA) based on Bray-Curtis dissimilarity illustrates the distinct 510 clustering of patients who experienced graft rejection (red circles) from those without rejection 511 (blue circles). Red and blue squares mark the respective centroids. G+H) Longitudinal analysis of 512 microbial diversity, depicted through Shannon diversity and Simpson evenness indices, shows a 513 reduction in both measures within the first-year post-transplantation for patients undergoing 514 rejection. Vertical red bars indicate individual rejection events over time, coinciding with alterations 515 in microbial diversity.

516

517 Figure 2. Microbiome alteration precede kidney transplant rejection. Patients with available fecal 518 samples prior to kidney rejection (Rejection group) for propensity score matched (1:2) to patients 519 without kidney rejection (Non-Rejection group). A) Plasma creatinine levels are depicted over time, 520 displaying a consistent increase within the first year post-transplant in patients who experienced 521 graft rejection (red), with these elevated levels persisting at follow-up. Vertical red bars indicate 522 individual rejection events over time. B) Analysis of minimum creatinine levels before and after 523 sampling, along with the time taken to reach the first. C) Gut microbial communities of the two 524 groups based on Bray-Curtis dissimilarity, demonstrate clear separation, with the rejection group

525 (red circles) showing distinct clustering from the non-rejection group (blue circles). Squares 526 represent the centroids of the groups. D) Microbial diversity metrics, including number of detected 527 OTUs, Shannon diversity, and Simpson evenness. E) Differences in microbial taxa between groups, 528 highlighting a decrease in short-chain fatty acid (SCFA)-producing bacteria in the rejection group and 529 an enrichment of genera commonly elevated in chronic kidney disease (CKD) and disease conditions. 530 Bacteria are shown in a phylogenetic tree where green lineages represent bacteria depleted and 531 pink bacteria enriched in patients with kidney rejection F) Differential abundance analysis of 532 bacterial genera, with significant changes identified between non-rejection and rejection groups. 533 Cliff's Delta values indicate the direction and extent of these differences. Blue dots show genera 534 increased in the non-rejection group and red increased in the rejection group.

535

536 Figure 3. Fecal short-chain fatty acid production potential is reduced before kidney transplant 537 **rejection.** Patients with available fecal samples prior to kidney rejection (Rejection group) for 538 propensity score matched (1:2) to patients without kidney rejection (Non-Rejection group). 539 Inference of functional data from taxonomic data using PICRUSt2 and mapping to pathways using 540 GOmixer. A) Clustering of kidney transplant recipients based on the presence (red circles) or absence 541 (blue circles) of graft rejection, illustrating differences in microbiome-derived functional potential. 542 Squares represent centroids. B) Functional pathways highlight an increase in proteolytic 543 fermentation and reactive nitrogen and oxygen species production pathways in patients who 544 experienced graft rejection (red). Non-rejection samples show enhanced pathways related to sugar 545 and polysaccharide metabolism, and mucus degradation (blue). C) Heatmap shows all 54 significant 546 GOmixer modules, with pink indicating high predicted abundances and green representing low 547 abundances across the 92 patients, divided into non-rejection and rejection. Blue dots denote 548 negative log2 fold changes, indicating enhanced modules in non-rejection samples compared to

rejection samples, while red dots represent positive log2 fold changes, signifying an increase in patients experiencing graft rejection.

551

552 Figure 4. Decreased abundance of short-chain fatty acid producing enzymes in the microbiome 553 before kidney transplant rejection. Patients with available fecal samples prior to kidney rejection 554 (Rejection group) for propensity score matched (1:2) to patients without kidney rejection (Non-555 Rejection group). A) Bacterial nutrient metabolism leading to SCFA, specifically butyrate and 556 propionate, production. Key bacterial enzymes highlighted in red. B) Abundance of bacterial 557 enzymes for SCFA production were assessed by qPCR from fecal DNA and normalized to 16s content. 558 While *bcd* was not significantly altered *but* and *mmdA* showed lower abundance in fecal samples 559 from patients with subsequent kidney rejection compared to those without rejection.

560

561 Figure 5. Microbiome composition normalizes post-kidney transplant rejection. Patients with available fecal samples (sample 1) prior to kidney rejection (Rejection group) and sample 2 90-1000 562 563 days post-rejection were analyzed. Propensity score matched patients without kidney rejection 564 (Non-Rejection group) with two comparable samples were included as controls. A) Principal 565 Coordinates Analysis (PCoA) of microbiome samples based on Bray-Curtis dissimilarity demonstrates 566 a shift in the microbiome composition of rejection patients (red to purple) towards the non-rejection 567 group (blue) over time, suggesting a post-rejection stabilization. Squares represent centroids. B) 568 Microbial diversity measured by the number of detected OTU, Shannon diversity, and Simpson 569 evenness. C) Heatmap comparison of genus-level alterations between pre- and post-rejection 570 samples reveals significant directional changes in microbial populations after a rejection event, 571 contrasting with the stable profiles observed in non-rejection controls. Pre-rejection comparison 572 taken from Figure 3F. Asterisks indicate significance levels: FDR < 0.1 * FDR <0.01 ** FDR <0.001 ***. 573 Confounded signals are shown as circles. Effect size is shown as Cliffs delta with pink enriched and

574 green depleted. D) Boxplots show shifts at the genus level, of short-chain fatty acid producers,

575 Blautia and Faecalibacterium, and disease-associated genera, Fusobacterium and Streptococcus.

577	Figure 6. Microbiome composition in kidney rejection partly mirrors CKD-related microbiome
578	alterations. Correlation between CKD microbial signatures and kidney transplant rejection preceding
579	signatures. A) Scatter plot indicating the correlation between the microbial signatures observed
580	before kidney transplant (KT) rejections and those seen in chronic kidney disease (CKD) patients,
581	suggesting shared alterations. Dashed line indicates perfect overlap of effect sizes. B) Log
582	transformed rarefied abundance of key SCFA-producing genera (Blautia and Faecalibacterium) and
583	disease-associated genera (Streptococcus and Fusobacterium) across healthy controls (HC), CKD
584	patients, and KT recipients preceding graft rejection or without graft rejection (propensity-score
585	matched). C) Abundance of bacterial taxa involved in butyrate and propionate production between
586	HC and CKD patients, reflecting a decrease in these beneficial taxa in CKD.

587 References

588	1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. Mar 25
589	2017;389(10075):1238-1252. doi:10.1016/S0140-6736(16)32064-5
590	2. Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. <i>N Engl</i>
591	J Med. Aug 19 2021;385(8):729-743. doi:10.1056/NEJMra2014530
592	3. Cooper JE. Evaluation and Treatment of Acute Rejection in Kidney Allografts. <i>Clin J Am Soc</i>
594	4 Belkaid Y Hand TW Role of the microbiota in immunity and inflammation <i>Cell</i> Mar 27
595	2014;157(1):121-141. doi:10.1016/j.cell.2014.03.011
596 597	5. Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. <i>Immunity</i> . Apr 18 2017:46(4):562-576. doi:10.1016/j.jmmuni.2017.04.008
598	6. Behrens F. Bartolomaeus H. Wilck N. Holle J. Gut-immune axis and cardiovascular risk in
599	chronic kidney disease. Clin Kidney J. Jan 2024;17(1):sfad303. doi:10.1093/ckj/sfad303
600	7. Schlender J, Behrens F, McParland V, et al. Bacterial metabolites and cardiovascular risk in
601	children with chronic kidney disease. <i>Mol Cell Pediatr</i> . Oct 22 2021;8(1):17. doi:10.1186/s40348-021-
602	00126-8
603	8. Holle J, Bartolomaeus H, Lober U, et al. Inflammation in Children with CKD Linked to Gut
604	Dysbiosis and Metabolite Imbalance. <i>J Am Soc Nephrol</i> . Dec 2022;33(12):2259-2275.
605	doi:10.1681/ASN.2022030378
606	9. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids,
607	regulate colonic Treg cell homeostasis. <i>Science</i> . Aug 2 2013;341(6145):569-573.
608	doi:10.1126/science.1241165
609	10. Swarte JC, Douwes RM, Hu S, et al. Characteristics and Dysbiosis of the Gut Microbiome in
610	Renal Transplant Recipients. J Clin Med. Feb 1 2020;9(2)doi:10.3390/jcm9020386
611	11. Lee JR, Magruder M, Zhang L, et al. Gut microbiota dysplosis and diarrhea in kidney
01Z 612	12 Ericko WE Maddov C Song V Bromborg IS Human microbiota characterization in the course
614	of ropal transplantation Am / Transplant Eph 2014:14/2):416 427 doi:10.1111/ait 12588
615	13 Swarto IC Li V Hu S at al Gut microbiomo dysbiosis is associated with increased mortality
616	after solid organ transplantation. Sci Transl Med. Aug 31 2022:14/660):eabn7566
617	doi:10.1126/scitrans/med.ahn7566
618	14 Lei YM Chen I. Wang Y. et al. The composition of the microbiota modulates allograft
619	rejection. J Clin Invest. Jul 1 2016;126(7):2736-2744. doi:10.1172/JCl85295
620	15. Sato Y, Yanagita M. Immunology of the ageing kidney. <i>Nature reviews Nephrology</i> . Oct
621	2019;15(10):625-640. doi:10.1038/s41581-019-0185-9
622	16. Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis
623	and disease. <i>Nature</i> . Nov 30 2017;551(7682):585-589. doi:10.1038/nature24628
624	17. Bartolomaeus H, Balogh A, Yakoub M, et al. Short-Chain Fatty Acid Propionate Protects From
625	Hypertensive Cardiovascular Damage. <i>Circulation</i> . Mar 12 2019;139(11):1407-1421.
626	doi:10.1161/CIRCULATIONAHA.118.036652
627	18. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-Specific Tolerance of
628	Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. J Am Soc
629	Nephrol. Jun 1 2020;doi:10.1681/ASN.2019080852
630	19. Singer J, Li YJ, Ying T, et al. Protocol for a pilot single-centre, parallel-arm, randomised
631	controlled trial of dietary inulin to improve gut health in solid organ transplantation: the DIGEST
632	study. <i>BINJ Open</i> . 2021;11(4)
633 624	20. Sawitzki B, Harden PN, Keinke P, et al. Kegulatory cell therapy in kidney transplantation (The
635	trials. Lancet. May 23 2020;395(10237):1627-1639. doi:10.1016/S0140-6736(20)30167-7

636 21. Karch A, Schindler D, Kuhn-Steven A, et al. The transplant cohort of the German center for 637 infection research (DZIF Tx-Cohort): study design and baseline characteristics. Eur J Epidemiol. Feb 638 2021;36(2):233-241. doi:10.1007/s10654-020-00715-3 639 Deutsche Stiftung Organtransplantation (German Organ Procurement Organization). 22. 640 Nierentransplantation: Grafiken zum Tätigkeitsbericht 2022 nach § 11 Abs. 5 TPG. 2022. 641 23. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of 642 kidney transplant recipients: a summary. Kidney Int. Feb 2010;77(4):299-311. 643 doi:10.1038/ki.2009.377 644 24. Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Political Analysis. 2007;15(3):199-236. 645 646 doi:10.1093/pan/mpl013 647 Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on 25. 648 and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. Sep 649 2020;20(9):2318-2331. doi:10.1111/ajt.15898 650 26. Ren Z, Fan Y, Li A, et al. Alterations of the Human Gut Microbiome in Chronic Kidney Disease. 651 Adv Sci (Weinh). Oct 2020;7(20):2001936. doi:10.1002/advs.202001936 652 27. Lahti L, Sudarshan S. microbiome R package. http://microbiome.github.io 653 McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and 28. 654 Graphics of Microbiome Census Data. PLOS ONE. 2013;8(4):e61217. 655 doi:10.1371/journal.pone.0061217 656 Oksanen J, Blanchet FG, Kindt R, et al. Community ecology package. R package version. 29. 657 2013;2(0):321-326. 658 30. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al. Combinatorial, additive and 659 dose-dependent drug-microbiome associations. Nature. Dec 2021;600(7889):500-505. 660 doi:10.1038/s41586-021-04177-9 661 31. Chen C-Y, Lizber U, Forslund SK. LongDat: an R package for covariate-sensitive longitudinal 662 analysis of high-dimensional data. Bioinformatics Advances. 2023;doi:10.1093/bioadv/vbad063 663 32. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome functions. 664 Nature Biotechnology. 2020/06/01 2020;38(6):685-688. doi:10.1038/s41587-020-0548-6 665 Darzi Y, Falony G, Vieira-Silva S, Raes J. Towards biome-specific analysis of meta-omics data. 33. 666 ISME J. May 2016;10(5):1025-1028. doi:10.1038/ismej.2015.188 667 34. Notting F, Pirovano W, Sybesma W, Kort R. The butyrate-producing and spore-forming 668 bacterial genus Coprococcus as a potential biomarker for neurological disorders. Gut Microbiome. 669 2023;4:e16. e16. doi:10.1017/gmb.2023.14 670 35. Zhang J, Song L, Wang Y, et al. Beneficial effect of butyrate-producing Lachnospiraceae on 671 stress-induced visceral hypersensitivity in rats. J Gastroenterol Hepatol. Aug 2019;34(8):1368-1376. 672 doi:10.1111/jgh.14536 673 Kasahara K, Krautkramer KA, Org E, et al. Interactions between Roseburia intestinalis and 36. 674 diet modulate atherogenesis in a murine model. Nat Microbiol. Dec 2018;3(12):1461-1471. 675 doi:10.1038/s41564-018-0272-x 676 37. Lenoir M, Martín R, Torres-Maravilla E, et al. Butyrate mediates anti-inflammatory effects of 677 Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. Gut Microbes. Nov 9 678 2020;12(1):1-16. doi:10.1080/19490976.2020.1826748 679 38. Reichardt N, Duncan SH, Young P, et al. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. *ISME J.* Jun 2014;8(6):1323-1335. 680 681 doi:10.1038/ismej.2014.14 682 39. Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in the Gut 683 Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort. 684 Circulation. 2023;148(6):459-472. doi:doi:10.1161/CIRCULATIONAHA.123.063914 685 Gupta VK, Kim M, Bakshi U, et al. A predictive index for health status using species-level gut 40. 686 microbiome profiling. Nat Commun. Sep 15 2020;11(1):4635. doi:10.1038/s41467-020-18476-8

687 41. Stanisic D, Jeremic N, Singh M, Pushpakumar S, Mokshagundam SPL, Tyagi SC. 688 Porphyromonas gingivalis induces cardiovascular dysfunction. Can J Physiol Pharmacol. Aug 1 689 2023;101(8):413-424. doi:10.1139/cjpp-2022-0392 690 42. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships shape ecological 691 properties of the human gut microbiome. Nat Microbiol. Jun 13 2016;1(8):16088. 692 doi:10.1038/nmicrobiol.2016.88 693 43. Wang X, Yang S, Li S, et al. Aberrant gut microbiota alters host metabolome and impacts 694 renal failure in humans and rodents. Gut. Dec 2020;69(12):2131-2142. doi:10.1136/gutjnl-2019-695 319766 696 Stubbs JR, House JA, Ocque AJ, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and 44. 697 Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. Jan 2016;27(1):305-313. 698 doi:10.1681/ASN.2014111063 699 45. Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl Sulfate and p-Cresyl Sulfate Promote 700 Vascular Calcification and Associate with Glucose Intolerance. J Am Soc Nephrol. May 701 2019;30(5):751-766. doi:10.1681/ASN.2018060609 702 Holle J, Kirchner M, Okun J, et al. Serum indoxyl sulfate concentrations associate with 46. 703 progression of chronic kidney disease in children. PLoS One. 2020;15(10):e0240446. 704 doi:10.1371/journal.pone.0240446 705 47. Gacesa R, Kurilshikov A, Vich Vila A, et al. Environmental factors shaping the gut microbiome 706 in a Dutch population. Nature. 2022/04/01 2022;604(7907):732-739. doi:10.1038/s41586-022-707 04567-7 708 Avery EG, Bartolomaeus H, Rauch A, et al. Quantifying the impact of gut microbiota on 48. 709 inflammation and hypertensive organ damage. Cardiovasc Res. Jul 29 2022;doi:10.1093/cvr/cvac121 710 49. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome, 711 short-chain fatty acids and metabolic diseases. Nat Genet. Apr 2019;51(4):600-605. 712 doi:10.1038/s41588-019-0350-x 713 Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune 50. 714 tolerance and autoimmunity. Cellular & Molecular Immunology. 2023/04/01 2023;20(4):341-350. 715 doi:10.1038/s41423-023-00987-1 716 Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial 51. 717 communities using 16S rRNA marker gene sequences. Nature Biotechnology. 2013/09/01 718 2013;31(9):814-821. doi:10.1038/nbt.2676 719 Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote 52. 720 peripheral regulatory T-cell generation. Nature. Dec 19 2013;504(7480):451-455. 721 doi:10.1038/nature12726 722 53. Wu H, Singer J, Kwan TK, et al. Gut Microbial Metabolites Induce Donor-Specific Tolerance of 723 Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids. Journal of the 724 American Society of Nephrology. 2020;31(7) 725 54. Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney 726 transplant recipient: epidemiology, diagnosis and management strategies. Nephrology Dialysis 727 Transplantation. 2019;34(5):760-773. doi:10.1093/ndt/gfz053 728 55. Lee JR, Muthukumar T, Dadhania D, et al. Gut microbial community structure and 729 complications after kidney transplantation: a pilot study. Transplantation. Oct 15 2014;98(7):697-730 705. doi:10.1097/tp.000000000000370 731 Wang J, Li X, Wu X, et al. Gut microbiota alterations associated with antibody-mediated 56. 732 rejection after kidney transplantation. Appl Microbiol Biotechnol. Mar 2021;105(6):2473-2484. 733 doi:10.1007/s00253-020-11069-x













Non-Rejection 🔶 Rejection



1400.0

2010.0

0.333

0.500

~









С